Kareo vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Merged with PatientPop → Tebra 2021; $222M funding; $1B+ valuation; $72M 2023 (Golub); 100K providers; 90M patients; 1,000 employees; practice management/EHR leader
About
Kareo was founded in 2004 by Dan Rodrigues to build purpose-designed practice management and billing software for independent physician practices — a segment underserved by legacy healthcare IT vendors focused on hospital systems. The platform addressed the full administrative workflow of a small medical practice: appointment scheduling, patient registration, insurance eligibility verification, charge capture, medical billing, and accounts receivable management. Kareo also developed an integrated EHR module, making it one of the few vendors to combine clinical documentation and practice management in a cloud-native platform accessible to solo practitioners.\n\nKareo's products included Kareo Billing for RCM, Kareo Clinical for EHR and documentation, and Kareo Engage for patient communication and online reputation management. The platform served primary care, mental health, physical therapy, and chiropractic specialties. Its cloud-based delivery — accessible via browser and mobile without on-premises infrastructure — resonated strongly with independent practices managing lean overhead. A managed RCM service and QuickBooks integration rounded out the offering.\n\nKareo merged with PatientPop, a digital practice growth platform, in 2021 to form Tebra — targeting the full lifecycle of independent practice management from marketing through billing. The combined company has raised $222 million in total funding, achieved a $1 billion+ valuation, and serves over 100,000 providers across 90 million patients. Tebra continues operating the Kareo brand for billing and EHR while integrating PatientPop's digital presence capabilities into a unified independent practice growth platform.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.